Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models

BMC Bioinformatics

Volumn 15, Issue 1, 2014, Pages

  Martin, Florian ^a   Sewer, Alain ^a   Talikka, Marja ^a   Xiang, Yang ^a   Hoeng, Julia ^a   Peitsch, Manuel C ^a  

^a Biological Systems Research   (Switzerland)

Author keywords

Causal network model; Systems biology; Transcriptomics data

Indexed keywords

ANTI-INFLAMMATORY DRUGS; CAUSAL NETWORK; DIFFERENTIAL EXPRESSIONS; HIGH-THROUGHPUT MEASUREMENTS; QUANTITATIVE MEASURES; SYSTEMS BIOLOGY; SYSTEMS TOXICOLOGIES; TRANSCRIPTOMICS;

CELL PROLIFERATION;

ANTIINFLAMMATORY AGENT;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; DOSE RESPONSE; GENE EXPRESSION PROFILING; HUMAN; METHODOLOGY; PHENOTYPE; SYSTEMS BIOLOGY; TOXICOLOGY; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE; SYSTEMS BIOLOGY; TOXICOLOGY;

EID: 84904074764     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-238     Document Type: Article

References (105)

1. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 2012, 8(2):1002375.
2. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550.
3. Huang DAW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37(1):1-13.
4. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004, 5(2):101-113.
5. Mewes HW, Frishman D, Guldener U, Mannhaupt G, Mayer K, Mokrejs M, Morgenstern B, Munsterkotter M, Rudd S, Weil B. MIPS: a database for genomes and protein sequences. Nucleic Acids Res 2002, 30(1):31-34.
6. Xenarios I, Salwinski L, Duan XJ, Higney P, Kim SM, Eisenberg D. DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res 2002, 30(1):303-305.
7. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli L, Cesareni G. MINT: the Molecular INTeraction database. Nucleic Acids Res 2007, 35(Database issue):572-574.
8. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. Genome Res 2007, 17(10):1537-1545.
9. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003, 4:117.
10. Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, Chen X, Li L, Wu S, Chen Y, Jiang H, Tan L, Xie J, Zhu X, Liang S, Deng H. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai) 2008, 40:426-436.
11. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007, 6(3):820-832.
12. Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, Chen X, Li L, Wu S, Chen Y, Jiang H, Tan L, Xie J, Zhu X, Liang S, Deng H. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai) 2008, 40(5):426-436.
13. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature 2011, 473(7347):337-342.
14. Mitrea C, Taghavi Z, Bokanizad B, Hanoudi S, Tagett R, Donato M, Voichita C, Draghici S. Methods and approaches in the topology-based analysis of biological pathways. Front Physiol 2013, 4:278.
15. Castillo-Davis CI, Hartl DL. Genemerge-post-genomic analysis, data mining, and hypothesis testing. Bioinformatics 2003, 19(7):891-892.
16. Tomfohr J, Lu J, Kepler TB. Pathway level analysis of gene expression using singular value decomposition. BMC Bioinformatics 2005, 6:225.
17. Shojaie A, Michailidis G. Analysis of gene sets based on the underlying regulatory network. J Comput Biol 2009, 16(3):407-426.
18. Komurov K, Dursun S, Erdin S, Ram PT. NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 2012, 13:282.
19. Liao JC, Boscolo R, Yang Y-L, Tran LM, Sabatti C, Roychowdhury VP. Network component analysis: reconstruction of regulatory signals in biological systems. Proc Nat Acad Sci 2003, 100(26):15522-15527.
20. Lefebvre C, Rajbhandari P, Alvarez M, Bandaru P, Lim W, Sato M, Wang K, Sumazin P, Kustagi M, Bisikirska B, Basso K, Beltrao P, Krogan N, Gautier J, Dalla-Favera R, Califano A. A human b-cell interactome identifies myb and foxm1 as master regulators of proliferation in germinal centers. Mol Syst Biol 2010, 6:377.
21. Catlett NL, Bargnesi AJ, Ungerer S, Seagaran T, Ladd W, Elliston KO, Pratt D. Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data. BMC Bioinformatics 2013, 14(1):340.
22. Ackermann M, Strimmer K. A general modular framework for gene set enrichment analysis. BMC Bioinformatics 2009, 10:47.
23. Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, Peitsch MC. Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks. BMC Syst Biol 2012, 6:54.
24. Schlage WK, Westra JW, Gebel S, Catlett NL, Mathis C, Frushour BP, Hengstermann A, Van Hooser A, Poussin C, Wong B, Lietz M, Park J, Drubin D, Veljkovic E, Peitsch MC, Hoeng J, Deehan R. A computable cellular stress network model for non-diseased pulmonary and cardiovascular tissue. BMC Syst Biol 2011, 5:168.
25. Westra JW, Schlage WK, Frushour BP, Gebel S, Catlett NL, Han W, Eddy SF, Hengstermann A, Matthews AL, Mathis C, Lichtner RB, Poussin C, Talikka M, Veljkovic E, Van Hooser AA, Wong B, Maria MJ, Peitsch MC, Deehan R, Hoeng J. Construction of a computable cell proliferation network focused on non-diseased lung cells. BMC Syst Biol 2011, 5:105.
26. Gebel S, Lichtner RB, Frushour B, Schlage WK, Hoang V, Talikka M, Hengstermann A, Mathis C, Veljkovic E, Peck M, Peitsch MC, Deehan R, Hoeng J, Westra JW. Construction of a computable network model for dna damage, autophagy, cell death, and senescence. Bioinform Biol Insights 2013, 7:97-117.
27. Westra J, Schlage W, Hengstermann A, Gebel S, Mathis C, Thomson T, Wong B, Hoang V, Veljkovic E, Peck M, Lichtner R, Weisensee D, Talikka M, Deehan R, Hoeng J, Peitsch M. A modular cell-type focused inflammatory process network model for non-diseased pulmonary tissue. Bioinform Biol Insights 2013, 7:167-192.
28. Ansari S, Binder J, Boue S, Di Fabio A, Hayes W, Hoeng J, Iskandar A, Kleiman R, Norel R, O'Neel B, Peitsch MC, Poussin C, Pratt D, Rhrissorrakrai K, Schlage WK, Stolovitzky G, Talikka M. The sbv IMPROVER project team: On crowd-verification of biological networks. Bioinform Biol Insight 2013, 7:307-325. http://www.la-press.com/on-crowd-verification-of-biological-networks-article-a3910.
29. Selventa OpenBEL. 2013, http://www.openbel.org/, Selventa.
30. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752. Sørlie T.
31. Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, Price ND, Hood LE, Tian Q. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci USA 2011, 108:1591-1596.
32. Froehlich H. Network-based consensus gene signatures for biomarker discovery in breast cancer. PLoS ONE 2011, 6(10):25364.
33. Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput Biol 2008, 4:1000217.
34. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007, 3:140.
35. Rapaport F, Zinovyev A, Dutreix M, Barillot E, Vert JP. Classification of microarray data using gene networks. BMC Bioinformatics 2007, 8:35.
36. Su J, Yoon BJ, Dougherty ER. Identification of diagnostic subnetwork markers for cancer in human protein-protein interaction network. BMC Bioinformatics 2010, 11(Suppl 6):8.
37. Cun Y, Frohlich H. Network and data integration for biomarker signature discovery via network smoothed T-statistics. PLoS ONE 2013, 8(9):73074.
38. Chen L, Xuan J, Riggins RB, Clarke R, Wang Y. Identifying cancer biomarkers by network-constrained support vector machines. BMC Syst Biol 2011, 5:161.
39. Andersen ME, Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci 2009, 107(2):324-330.
40. Nam D, Kim SY. Gene-set approach for expression pattern analysis. Brief Bioinformatics 2008, 9(3):189-197.
41. Hoeng J, Deehan R, Pratt D, Martin F, Sewer A, Thomson TM, Drubin DA, Waters CA, de Graaf D, Peitsch MC. A network-based approach to quantifying the impact of biologically active substances. Drug Discov Today 2012, 17(9-10):413-418.
42. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:3.
43. Kramer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 2014, 30(4):523-530.
44. Chindelevitch L, Ziemek D, Enayetallah A, Randhawa R, Sidders B, Brockel C, Huang ES. Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics 2012, 28(8):1114-1121.
45. Markowetz F, Kostka D, Troyanskaya OG, Spang R. Nested effects models for high-dimensional phenotyping screens. Bioinformatics 2007, 23(13):305-312.
46. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, Kim CJ, Kusanovic JP, Romero R. A novel signaling pathway impact analysis. Bioinformatics 2009, 25(1):75-82.
47. Belkin M, Partha N. Semi-supervised learning on riemannian manifolds. Mach Learn 2004, 56:209-239.
48. Chung FRK. Spectral Graph Theory. Vol. 92 1997, American Mathematical Soc, http://books.google.ch/books?id=YUc38_MCuhAC.
49. Goncalves JP, Francisco AP, Moreau Y, Madeira SC. Interactogeneous: disease gene prioritization using heterogeneous networks and full topology scores. PLoS ONE 2012, 7(11):49634.
50. Jacob L, Neuvial P, Dudoit S. More power via graph-structured tests for differential expression of gene networks. Ann Appl Stat 2012, 6(2):561-600.
51. Hou YP, Li J, Pan Y, Dewey C. On the Laplacian eigenvalues of signed graphs. Linear Multilinear Algebra 2003, 51(1):21-30.
52. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2007, 1(1):107-129.
53. Tarca AL, Lauria M, Unger M, Bilal E, Boue S, Kumar Dey K, Hoeng J, Koeppl H, Martin F, Meyer P, Nandy P, Norel R, Peitsch M, Rice JJ, Romero R, Stolovitzky G, Talikka M, Xiang Y, Zechner C. Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics 2013, 29(22):2892-2899.
54. Tarca AL, Than NG, Romero R. Methodological approach from the best overall team in the improver diagnostic signature challenge. Syst Biomed 2013, 1(4):24-34.
55. Breiman L. Random forests. Mach Learn 2001, 45(1):5-32.
56. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99:6567-6572.
57. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
58. Gebel S, Gerstmayer B, Kuhl P, Borlak J, Meurrens K, Muller T. The kinetics of transcriptomic changes induced by cigarette smoke in rat lungs reveals a specific program of defense, inflammation, and circadian clock gene expression. Toxicol Sci 2006, 93(2):422-431.
59. Kogel U, Schlage WK, Martin F, Xiang Y, Ansari S, Leroy P, Vanscheeuwijck P, Gebel S, Buettner A, Wyss C, Esposito M, Hoeng J, Peitsch MC. A 28-day rat inhalation study with an integrated molecular toxicology endpoint demonstrates reduced exposure effects for a prototypic modified risk tobacco product compared with conventional cigarettes. Food Chem Toxicol 2014, 68C:204-217.
60. Shan B, Farmer AA, Lee WH. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ 1996, 7(6):689-697.
61. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J. G1 control in mammalian cells. J Cell Sci Suppl 1994, 18:69-73.
62. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9(10):1149-1163.
63. Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 1991, 65(6):1063-1072.
64. Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JY. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 1991, 10(4):857-864.
65. Hollingsworth RE, Chen PL, Lee WH. Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr Opin Cell Biol 1993, 5(2):194-200.
66. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol 2007, 8(9):201.
67. Strulovici-Barel Y, Omberg L, O'Mahony M, Gordon C, Hollmann C, Tilley AE, Salit J, Mezey J, Harvey BG, Crystal RG. Threshold of biologic responses of the small airway epithelium to low levels of tobacco smoke. Am J Respir Crit Care Med 2010, 182(12):1524-1532.
68. Harvey BG, Heguy A, Leopold PL, Carolan BJ, Ferris B, Crystal RG. Modification of gene expression of the small airway epithelium in response to cigarette smoking. J Mol Med 2007, 85(1):39-53.
69. Chari R, Lonergan KM, Ng RT, MacAulay C, Lam WL, Lam S. Effect of active smoking on the human bronchial epithelium transcriptome. BMC Genomics 2007, 8:297.
70. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999, 36(6):425-438.
71. Aoshiba K, Nagai A. Oxidative stress, cell death, and other damage to alveolar epithelial cells induced by cigarette smoke. Tob Induc Dis 2003, 1(3):219-226.
72. Gebremichael A, Tullis K, Denison MS, Cheek JM, Pinkerton KE. Ah-receptor-dependent modulation of gene expression by aged and diluted sidestream cigarette smoke. Toxicol Appl Pharmacol 1996, 141(1):76-83.
73. Villard PH, Seree EM, Re JL, De Meo M, Barra Y, Attolini L, Dumenil G, Catalin J, Durand A, Lacarelle B. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA. Toxicol Appl Pharmacol 1998, 148(2):195-204.
74. Rakoff-Nahoum S, Bousvaros A. Innate and adaptive immune connections in inflammatory bowel diseases. Curr Opin Gastroenterol 2010, 26(6):572-577.
75. Steinhart H. Clinical perspectives-biologics in IBD: What's all the fuss?. Can J Gastroenterol 2001, 15(12):799-804.
76. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
77. Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med 2011, 6 Suppl 1:17-27.
78. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001, 120(6):1347-1355.
79. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 58(12):1612-1619.
80. Arijs I, Quintens R, Van Lommel L, Van Steen K, De Hertogh G, Lemaire K, Schraenen A, Perrier C, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010, 16(12):2090-2098.
81. Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13(2):123-128.
82. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps EM, Perez-Pariente JM, Lopez-Vazquez A, de Francisco R, Rodrigo L. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002, 97(9):2350-2356.
83. Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012, 47(5):538-547.
84. Watson AJ, Tremelling M. Mucosal gene expression signatures that predict response of ulcerative colitis to infliximab. Gastroenterology 2011, 140:729-731.
85. Carvalho FA, Nalbantoglu I, Ortega-Fernandez S, Aitken JD, Su Y, Koren O, Walters WA, Knight R, Ley RE, Vijay-Kumar M, Gewirtz AT. Interleukin-1 β (IL-1 β) promotes susceptibility of Toll-like receptor 5 (TLR5) deficient mice to colitis. Gut 2012, 61(3):373-384.
86. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991, 12(11):404-410.
87. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006, 25(2):319-329.
88. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010, 16(9):1583-1597.
89. Sandborn WJ, Faubion WA. Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep 2000, 2(6):440-445.
90. Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS ONE 2009, 4(11):7984.
91. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-kB pathway. FEBS J 2011, 278(6):862-876.
92. Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009, 44(6):727-735.
93. Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 2007, 13(1):65-70.
94. Bai JP, Abernethy DR. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu Rev Pharmacol Toxicol 2013, 53:451-473.
95. Toedter G, Li K, Sague S, Ma K, Marano C, Macoritto M, Park J, Deehan R, Matthews A, Wu GD, Lewis JD, Arijs I, Rutgeerts P, Baribaud F. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm Bowel Dis 2012, 18(8):1399-1410.
96. Araki A, Kanai T, Ishikura T, Makita S, Uraushihara K, Iiyama R, Totsuka T, Takeda K, Akira S, Watanabe M. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005, 40(1):16-23.
97. Yu C, Shan T, Feng A, Li Y, Zhu W, Xie Y, Li N, Li J. Triptolide ameliorates Crohn's colitis is associated with inhibition of TLRs / NF-kappaB signaling pathway. Fitoterapia 2011, 82(4):709-715.
98. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG, Isaacs JD. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFkappaB signalling pathways. Ann Rheum Dis 2010, 69(7):1315-1320.
99. Ey B, Eyking A, Gerken G, Podolsky DK, Cario E. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 2009, 284(33):22332-22343.
100. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132(4):1359-1374.
101. Di Sabatino A, Biancheri P, Piconese S, Rosado MM, Ardizzone S, Rovedatti L, Ubezio C, Massari A, Sampietro GM, Foschi D, Porro GB, Colombo MP, Carsetti R, MacDonald TT, Corazza GR. Peripheral regulatory T cells and serum transforming growth factor- β: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010, 16(11):1891-1897.
102. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 2008, 125(2):145-153.
103. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-like receptors: regulating the regulators. Ann Rheum Dis 2007, 66 Suppl 3:91-95.
104. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006, 290(6):1157-1163.
105. Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, Weiss J, Feeney D. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006, 368(9538):855-863.